ReviewDiabetologia2024
Bone metabolism in diabetes: a clinician's guide to understanding the bone-glucose interplay.
Review in Diabetologia, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Differential effects of GLP-1 receptor agonists on diabetic osteopathy in type 2 diabetes: a patient-stratified network meta-analysis.BMC musculoskeletal disorders · 2025Pooled it
- The Effect of Type 2 Diabetes on Bone Quality: A Systematic Review and Meta-Analysis of Cohort Studies.International journal of environmental research and public health · 2025Pooled it
- Disorganized bone collagen fibers in early-stage type 2 diabetes mellitus and its association with adipose tissue redistribution.European radiology experimental · 2026Article
- The Liver-Bone Axis in Steatotic Liver Disease.Calcified tissue international · 2026Review
- Alogliptin Enhances Implant Osseointegration in Diabetes Through an Osteogenic-Angiogenic Immunomodulatory Procedure.International journal of molecular sciences · 2026Article
- Smart immunomodulatory polysaccharide hydrogels promote diabetic bone regeneration by regulating the inflammation-angiogenesis-osteogenesis axis.Materials today. Bio · 2026Article
- Effects of spironolactone on cytotoxic damage in osteoblasts.Experimental and therapeutic medicine · 2026Article
- Beyond M1/M2: The Pivotal Role of Macrophage Metabolic Reprogramming in Chronic Bone Disease and Targeted Intervention.International journal of molecular sciences · 2026Review
- HIF-1α and BMAL1 in bone regeneration: crosstalk between hypoxia response and circadian rhythm.Bone research · 2026Review
- All-natural medicine food homology herb-based self-gelling hemostatic powder for rapid hemostasis and diabetic wound management.Journal of nanobiotechnology · 2026Article
- Association between frailty index and hip fracture among Chinese middle- and old-aged adults in different glycemic status: a prospective study from the China Health and Retirement Longitudinal Study (CHARLS).International journal of surgery (London, England) · 2026Article
- Serum 25-hydroxyvitamin D is associated with islet function in postmenopausal women with type 2 diabetes and osteoporosis.Frontiers in endocrinology · 2026Article
- Sex-Stratified Association of Serum Uric Acid With Multisite Bone Mineral Density Among Inpatients With Type 2 Diabetes: A Cross-Sectional Study.Journal of diabetes research · 2026Article
- Association of coexisting type 2 diabetes and DXA-defined low muscle mass with prevalent radiographic vertebral fracture in community-dwelling older adults: a cross-sectional study.Frontiers in public health · 2026Article
- Recent Advancements in Non-surgical Approaches for the Management of Delayed Union and Nonunion in Long Bone Fractures of the Extremities: A Review.Advances in therapy · 2026Review
- Exploring Causal Associations Between Plasma Metabolites and Sciatica: A Two-Sample Mendelian Randomization Analysis.Journal of pain research · 2026Article
- The association between the ZJU index and bone mineral density (BMD) among patients with type 2 diabetes mellitus.Metabolism open · 2025Article
- Current evidence and research gaps in menopause management in women with type 1 diabetes mellitus: a narrative review.Endocrine connections · 2025Review
- Correlation of gut microbiota metabolite trimethylamine N-oxide with inflammatory levels and osteoporosis in patients with diabetic nephropathy.World journal of diabetes · 2025Article
- Impact of high body fat and low muscle mass on bone mineral density in postmenopausal women with type 2 diabetes: A DXA-based cross-sectional study.Aging clinical and experimental research · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Skeletal fragility is an increasingly recognised, but poorly understood, complication of both type 1 and type 2 diabetes. Fracture risk varies according to skeletal site and diabetes-related characteristics. Post-fracture outcomes, including mortality risk, are worse in those with diabetes, placing these people at significant risk. Each fracture therefore represents a sentinel event that warrants targeted management. However, diabetes is a very heterogeneous condition with complex interactions between multiple co-existing, and highly correlated, factors that preclude a clear assessment of the independent clinical markers and pathophysiological drivers for diabetic osteopathy. Additionally, fracture risk calculators and routinely used clinical bone measurements generally underestimate fracture risk in people with diabetes. In the absence of dedicated prospective studies including detailed bone and metabolic characteristics, optimal management centres around selecting treatments that minimise skeletal and metabolic harm. This review summarises the clinical landscape of diabetic osteopathy and outlines the interplay between metabolic and skeletal health. The underlying pathophysiology of skeletal fragility in diabetes and a rationale for considering a diabetes-based paradigm in assessing and managing diabetic bone disease will be discussed.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.